Abstract
The characteristic phenomena of acute gouty arthritis are acute arthritis in a middle-aged male, associated with serum uric acid above 6 mg. per 100 cc. and a satisfactory response to colchicine. Roentgenographically observable changes do not occur early.
In recent years uric acid metabolism has been studied by means of isotope techniques utilizing labeled substances. Uric acid is excreted in relatively constant amounts by humans and is little affected by variations in dietary intake, except for purine or nucleic acid substances. Persons with gout have a greater total amount of uric acid and a lower turnover than normal persons.
In the treatment of acute attacks of gout colchicine is still the most practical single drug, even though its pharmacologic action remains unknown.
Benemid (probenecid) is a powerful uricosuric agent of low toxicity which has been subjected to extensive clinical trial for three years. It causes inhibition of the resorption of urate from the glomerular filtrate; the site of action is believed to be the tubular cells. The author's usual dose is 2 gm. a day. This has caused a lowering of the uric acid in the serum and an increase in the urinary output.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BENEDICT J. D., FORSHAM P. H., ROCHE M., SOLOWAY S., STETTEN D., Jr The effect of salicylates and adrenocorticotropic hormone upon the miscible pool of uric acid in gout. J Clin Invest. 1950 Aug;29(8):1104–1111. doi: 10.1172/JCI102343. [DOI] [PMC free article] [PubMed] [Google Scholar]
- BISHOP C., GARNER W., TALBOTT J. H. Pool size, turnover rate, and rapidity of equilibration of injected isotopic uric acid in normal and pathological subjects. J Clin Invest. 1951 Aug;30(8):879–888. doi: 10.1172/JCI102504. [DOI] [PMC free article] [PubMed] [Google Scholar]
- BISHOP C., RAND R., TALBOTT J. H. The effect of benemid (P-[DI-N-propylsulfamyl]-benzoic acid) on uric acid metabolism in one normal and one gouty subject. J Clin Invest. 1951 Aug;30(8):889–895. doi: 10.1172/JCI102505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- GUTMAN A. B., YU T. F. Current principles of management in gout. Am J Med. 1952 Dec;13(6):744–759. doi: 10.1016/0002-9343(52)90374-4. [DOI] [PubMed] [Google Scholar]
- KITTREDGE W. E., DOWNS R. The role of gout in the formation of urinary calculi. J Urol. 1952 Jun;67(6):841–849. doi: 10.1016/S0022-5347(17)68427-1. [DOI] [PubMed] [Google Scholar]
- KUZELL W. C., SCHAFFARZICK R. W., BROWN B., MANKLE E. A. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. J Am Med Assoc. 1952 Jun 21;149(8):729–734. doi: 10.1001/jama.1952.02930250011004. [DOI] [PubMed] [Google Scholar]
- PASCALE L. R., DUBIN A., HOFFMAN W. S. Therapeutic value of probenecid (benemid) in gout. J Am Med Assoc. 1952 Jul 26;149(13):1188–1194. doi: 10.1001/jama.1952.02930300014004. [DOI] [PubMed] [Google Scholar]
- WILSON D., BISHOP C., TALBOTT J. H. A factorial experiment to test the effect of various types of diets on uric acid excretion of normal human subjects. J Appl Physiol. 1952 Jan;4(7):560–565. doi: 10.1152/jappl.1952.4.7.560. [DOI] [PubMed] [Google Scholar]